Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mycobacterium Avium-Intracellulare Infection: early-phase trial registry
A small indexed set (9 trials) with no open enrollment listed right now.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · none currently recruiting · #1,916 of 28,707 conditions by registered trial count
Mycobacterium Avium-Intracellulare Infection: 9 US clinical trials tracked, none currently recruiting.
Mycobacterium Avium-Intracellulare Infection is the subject of 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 6 of these trials.
Enrollment posture brief
Registry condition mycobacterium-avium-intracellulare-infection
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #1916 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Mycobacterium Avium-Intracellulare Infection has no open enrollment in this registry pull (9 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mycobacterium Avium-Intracellulare Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mycobacterium Avium-Intracellulare Infection is recruiting below its size-band peers.
0 of 9 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mycobacterium Avium-Intracellulare Infection research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 6 of 9 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Mycobacterium Avium-Intracellulare Infection enrolment sits around 91 participants.
Median target enrolment is 91 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Mycobacterium Avium-Intracellulare Infection research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
9 total, page 1 of 1
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001030
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Pharmacia
NCT00002032
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000933
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001023
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000907
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001763
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00111397
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
Pfizer
NCT00002309
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Pharmacia
NCT00002080
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Named interventions
Most-linked intervention names on Mycobacterium Avium-Intracellulare Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mycobacterium Avium-Intracellulare Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mycobacterium Avium-Intracellulare Infection page
9 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Mycobacterium Avium-Intracellulare Infection trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Mycobacterium Avium-Intracellulare Infection trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mycobacterium Avium-Intracellulare Infection condition card totals 9 registered trials; most-linked intervention Rifabutin; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.